Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
about
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesPositron emission tomography to assess hypoxia and perfusion in lung cancerPhase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursHypoxia-inducible factor-1 as a therapeutic target in endometrial cancer managementEffectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy.Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells.Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.Imaging hypoxia in gliomas.The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancerF-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapySpecific recommendations for accurate and direct use of PET-CT in PET guided radiotherapy for head and neck sites.The role of PET in monitoring therapy.Optimizing hypoxia detection and treatment strategies.Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.Novel imaging approaches to head and neck cancerClinical biomarkers of angiogenesis inhibition.Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.Is there a role for tirapazamine in the treatment of cervical cancer?Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility studyHypoxia in head and neck squamous cell carcinomaTumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.Treatment response in the neck: p16+ versus p16- oropharyngeal cancer.
P2860
Q27025579-CED91D6E-1E0A-473C-97C2-6C770F2D4A43Q27026940-210B0301-92C2-4DA9-939E-4D3CF97D7F06Q30408170-95C90F2F-8688-4F93-94B1-E0ACD8565F10Q33278718-4A51E3AC-B74E-4F72-AE7A-BA8FF7C6E627Q33404024-2EA82EC3-BDC8-4746-8C0D-7B8DE0367D96Q33652379-A695ABE1-511E-4DE9-AF5C-92A373A67E64Q33972586-503E834A-F6B5-4F09-9254-23256875E5F9Q34022884-958C2D45-C366-45B0-BAFE-E7B0A17B8394Q34139877-C18ABF78-0523-472B-914A-D75E7CDC6C3AQ34203937-BD64EB5D-FBA8-413A-BD89-F69D55DEC66CQ34622547-42941EAD-1BEC-4DC4-9E6B-6822CB907B45Q35116993-8ACE11F9-45E8-4E57-AE14-FA3AD86EC407Q35138065-E662EDEF-A881-4283-B95C-C0CC86FAA190Q35172974-A6B92127-CF29-493D-9BAA-CAAB70829BF0Q35195185-0C4866AA-E88E-4ADE-AB49-CDE741CEB909Q35611873-D8FA3172-1610-4226-B7A2-B0A168D4CF47Q35967320-28C67F2B-7996-4B7D-9B70-88E82DE03AEBQ35975832-F5CAB889-00EB-4845-9E4E-E5D44C67AD22Q37012938-E594E78E-44D0-46C2-84E3-6620A2C05362Q37139413-4D83887B-24B7-4586-A58D-13EC590AF7CFQ37242284-80A81F1A-F737-4A84-B701-B0D216B9B51BQ37322050-3AED1854-178E-424E-B5D2-C6101569CBDEQ38049169-AF189CC1-8598-4004-B2BB-A7C30342B2C4Q38806173-C91A9DEF-AC05-43E6-B70A-D8E3BE9E1A7EQ38824983-71467344-FC7B-443E-8506-6BAF72FAA9B0Q39665208-9D0DE429-37AB-4A68-A2BC-54A886F307E1Q41195176-F0CB8793-1CFC-4A23-A810-F6AD30254358Q41480144-8835D7D3-9CF8-4105-87FE-C939BE75C9C6Q42545335-F9B34B7B-109A-45B1-BE0E-17534B4D7AB6Q44108779-5374C6D2-4DA1-48A1-A903-E89E16BF06FB
P2860
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@ast
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@en
type
label
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@ast
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@en
prefLabel
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@ast
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@en
P2093
P1476
Phase I trial of concurrent ti ...... advanced head and neck cancer.
@en
P2093
R von Roemeling
P304
P356
10.1200/JCO.2001.19.2.535
P407
P577
2001-01-01T00:00:00Z